JLE

Hématologie

MENU

Déficit congénital en facteur XIII en 2020 Prévalence, diagnostic clinique et biologique et modalités thérapeutiques Volume 26, numéro 4, Juillet-Août 2020

  • [1] Ivaskevicius V., Seitz R., Kohler H.P. International registry on factor XIII deficiency: a basis formed mostly on European data. Thromb Haemost. 2007;97:914-921. 6
  • [2] Muszbek L., Bagoly Z., Cairo A., Peyvandi F. Novel aspects of factor XIII deficiency. Curr Opin Hematol. 2011;18:366-372. 5
  • [3] Biswas A., Ivaskevicius V., Thomas A., Oldenburg J. Coagulation factor XIII deficiency. Diagnosis, prevalence and management of inherited and acquired forms. Hamostaseologie. 2014;34:160-166. 2
  • [4] Kohler H.P., Ichinose A., Seitz R., Ariens R.A.S., Muszbek L. Factor XIII and fibrinogen SSC subcommittee of the ISTH. Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost. 2011;9:1404-1406. 7
  • [5] Karimi M., Bereczky Z., Cohan N., Muszbek L. Factor XIII deficiency. Semin Thromb Hemost. 2009;35:426-438. 4
  • [6] Asahina T., Kobayashi T., Okada Y., Goto J., Terao T. Maternal blood coagulation factor XIII is associated with the development of cytotrophoblastic shell. Placenta. 2000;21:388-393. 4
  • [7] Hsieh L., Nugent D. Factor XIII deficiency. Haemophilia. 2008;14:1190-1200. 6
  • [8] Schroeder V., Kohler H.P. New developments in the area of factor XIII. Journal of Thrombosis and Haemostasis. 2013;11:234-244. 2
  • [9] Muszbek L., Bagoly Z., Bereczky Z., Katona E. The involvement of blood coagulation factor XIII in fibrinolysis and thrombosis. Cardiovasc Hematol Agents Med Chem. 2008;6:190-205. 3
  • [10] Ichinose A., Asahina T., Kobayashi T. Congenital blood coagulation factor XIII deficiency and perinatal management. Curr Drug Targets. 2005;6:541-549. 5
  • [11] Bottenus R.E., Ichinose A., Davie E.W. Nucleotide sequence of the gene for the b subunit of human factor XIII. Biochemistry. 1990;29:11195-11209. 51
  • [12] Webb G.C., Coggan M., Ichinose A., Board P.G. Localization of the coagulation factor XIII B subunit gene (F13B) to chromosome bands 1q31-32.1 and restriction fragment length polymorphism at the locus. Hum Genet. 1989;81:157-160. 2
  • [13] Board P.G., Webb G.C., McKee J., Ichinose A. Localization of the coagulation factor XIII A subunit gene (F13A) to chromosome bands. Cytogenet Cell Genet. 1988;48:25-27. 1
  • [14] Ma S., Chen C., Liang Q. Phenotype and genotype of FXIII deficiency in two unrelated probands: identification of a novel F13A1 large deletion mediated by complex rearrangement. Orphanet Journal of Rare Diseases. 2019;14:182. 1https://doi.org/10.1186/s13023-019-1144-z
  • [15] Peyvandi F., Palla R., Menegatti M. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European network of rare bleeding disorders. J Thromb Haemost. 2012;10:615-621. 4
  • [16] Menegatti M., Palla R., Boscarino M. Minimal factor XIII activity level to prevent major spontaneous bleeds. J Thromb Haemost. 2017;15:1728-1736. 9
  • [17] Naderi M., Cohan N., Shahramian I. A retrospective study on clinical manifestations of neonates with FXIII-A deficiency. Blood Cells Mol Dis. 2019;77:78-81.
  • [18] Bouttefroy S., Meunier S., Milien V. Congenital factor XIII deficiency: comprehensive overview of the FranceCoag cohort. Br J Haematol. 2020;188:317-320. 2
  • [19] Naderi M., Cohan N., Haghpanah S. Correlation of bleeding score with frequency and severity of bleeding symptoms in FXIII deficiency assessing by the ISTH Bleeding Assessment Tool. Transfus Apher Sci. 2019;58:495-497. 4
  • [20] Sharief L.A.T., Kadir R.A. Congenital factor XIII deficiency in women: a systematic review of literature. Haemophilia. 2013;19:e349-357. 6
  • [21] Rugeri L., Martinaud C., Beurrier P. Gynecological and obstetric outcome in the French cohort of women with factor XIII deficiency. Thrombosis Research. 2020;191:22-25.
  • [22] Dorgalaleh A., Tabibian S.H., Safa M., Shams M., Naderi M. Minimal factor XIII activity level to prevent major spontaneous bleeds: comment. J Thromb Haemost. 2017;15:2279-2280. 11
  • [23] Menegatti M., Palla R., Bucciarelli P., Peyvandi F. Minimal factor XIII activity level to prevent major spontaneous bleeds: reply. Journal of Thrombosis and Haemostasis. 2017;15:2280-2282. 11
  • [24] Karimi M., Peyvandi F., Naderi M., Shapiro A. Factor XIII deficiency diagnosis: challenges and tools. International Journal of Laboratory Hematology. 2018;40:3-11. 1
  • [25] Katona É., Pénzes K., Molnár É., Muszbek L. Measurement of factor XIII activity in plasma. Clinical chemistry and laboratory medicine (CCLM). 2012;50:1191-1202. 7
  • [26] Hsu P., Zantek N.D., Meijer P. Factor XIII Assays and associated problems for laboratory diagnosis of factor XIII deficiency: an analysis of International Proficiency testing results. Semin Thromb Hemost. 2014;40:232-238. 2
  • [27] Caron C., Meley R., Duchez V.L.C. Agreement between factor XIII activity and antigen assays in measurement of factor XIII: a French multicenter study of 147 human plasma samples. International Journal of Laboratory Hematology. 2017;39:279-285. 3
  • [28] Dargaud Y., de Mazancourt P., Rugeri L. An unusual clinical presentation of factor XIII deficiency and issues relating to the monitoring of factor XIII replacement therapy. Blood Coagul Fibrinolysis. 2008;19:447-452. 5
  • [29] Bouttefroy S., Meunier S., Jousselme E., Rugeri L. Benefits of thromboelastometry for monitoring replacement therapy in patients with severe inherited factor XIII deficiency: 3 illustrative cases. Haemophilia. 2019;25:e336-e338. 5
  • [30] Menegatti M., Peyvandi F. Treatment of rare factor deficiencies other than hemophilia. Blood. 2019;133:415-424. 5
  • [31] Mumford A.D., Ackroyd S., Alikhan R. Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors’ Organization guideline. Br J Haematol. 2014;167:304-326. British Committee for Standards in Haematology3
  • [32] Palla R., Peyvandi F., Shapiro A.D. Rare bleeding disorders: diagnosis and treatment. Blood. 2015;125:2052-2061. 13
  • [33] Nugent D.J., Ashley C., García-Talavera J., Lo L.C., Mehdi A.S., Mangione A. Pharmacokinetics and safety of plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency. Haemophilia. 2015;21:95-101. 1
  • [34] Dorgalaleh A., Naderi M., Hosseini M.S. Factor XIII deficiency in Iran: a comprehensive review of the literature. Semin Thromb Hemost. 2015;41:323-329. 3
  • [35] Ashley C., Chang E., Davis J., Mangione A., Frame V., Nugent D.J. Efficacy and safety of prophylactic treatment with plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency. Haemophilia. 2015;21:102-108. 1
  • [36] Peyvandi F., Menegatti M. Treatment of rare factor deficiencies in 2016. Hematology Am Soc Hematol Educ Program. 2016;2016:663-669. 1
  • [37] Dorgalaleh A., Rashidpanah J. Blood coagulation factor XIII and factor XIII deficiency. Blood Reviews. 2016;30:461-475. 6
  • [38] Muszbek L., Pénzes K., Katona É. Auto- and alloantibodies against factor XIII: laboratory diagnosis and clinical consequences. Journal of Thrombosis and Haemostasis. 2018;16:822-832. 5